Prothena Seeks Shareholder Nod for Capital Reduction to Boost Distributions

TL;DR

**PRTA is setting the stage for shareholder payouts; vote FOR the capital reduction to unlock potential buybacks and dividends!**

AI Summary

Prothena Corporation plc (PRTA) is holding an Extraordinary General Meeting (EGM) on November 19, 2025, to seek shareholder approval for a reduction of its Company capital. This capital reduction is specifically designed to facilitate the creation of distributable reserves, which are essential under Irish law for the company to repurchase or redeem shares, pay dividends, or make other distributions to shareholders. The Board of Directors unanimously recommends a 'FOR' vote on this proposal, which requires approval from at least 75% of the votes cast at the EGM. This strategic move aims to provide the Board with greater flexibility for future shareholder distributions, including a potential share redemption program, as previously referenced in a press release dated August 4, 2025. As of the September 24, 2025 record date, there were 53,829,928 ordinary shares issued and outstanding, with a quorum requiring 26,914,965 shares to be represented.

Why It Matters

This EGM is crucial for Prothena investors as it directly impacts the company's ability to return capital. By creating distributable reserves, Prothena gains the flexibility to initiate share redemptions or pay dividends, potentially increasing shareholder value. In a competitive biotech landscape where capital allocation is key, this move could signal a more mature financial strategy, making PRTA more attractive compared to peers that lack such financial maneuverability. Employees and customers are less directly impacted, but a stronger financial position can indirectly support long-term stability and investment in R&D.

Risk Assessment

Risk Level: low — The risk level is low because the proposal is a procedural step to enable future capital distributions, not a commitment to specific actions. The Board's unanimous recommendation and the requirement for a 75% shareholder approval suggest strong internal alignment and a clear strategic purpose. The reduction of capital itself, subject to Irish High Court confirmation, is a standard financial mechanism under Irish law.

Analyst Insight

Investors should vote 'FOR' Proposal No. 1 to empower Prothena's Board with the financial flexibility to return capital. This move could precede a share redemption program, potentially boosting PRTA's stock price. Monitor future announcements for specific details on share repurchases or dividend policies.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

0%

total Assets

$0

total Debt

$0

net Income

$0

eps

$0

gross Margin

0%

cash Position

$0

revenue Growth

0%

Key Numbers

• November 19, 2025 — Date of Extraordinary General Meeting (Shareholders will vote on capital reduction)
• 4:00 p.m. local time — Time of EGM (Meeting will be held in Dublin, Ireland)
• September 24, 2025 — Record Date for EGM (Shareholders owning shares on this date can vote)
• 53,829,928 — Ordinary shares issued and outstanding (Total shares eligible to vote as of Record Date)
• 26,914,965 — Ordinary shares required for quorum (Represents a majority of issued and outstanding shares)
• 75% — Approval threshold for Proposal No. 1 (Required percentage of votes cast for special resolution)
• $0.01 — Par value per ordinary share (Nominal value of Prothena's shares)
• August 4, 2025 — Date of press release (Referenced potential share redemption program)
• October 7, 2025 — Proxy Statement availability date (Materials made available to shareholders)
• November 18, 2025 — Proxy voting deadline (11:59 p.m. Eastern Time for internet/telephone/written proxy)

Key Players & Entities

• PROTHENA CORP PUBLIC LTD CO (company) — Registrant
• Daniel G. Welch (person) — Chair of the Board
• Gene G. Kinney Ph.D. (person) — President and Chief Executive Officer, Director
• Michael J. Malecek (person) — Chief Legal Officer & Company Secretary
• A&L Goodbody LLP (company) — Company's legal counsel and EGM venue
• Computershare Trust Company, N.A. (company) — Transfer agent for ordinary shares
• Broadridge Financial Solutions, Inc. (company) — Independent agent to tabulate shareholder votes
• U.S. Securities and Exchange Commission (regulator) — Regulatory body
• Irish High Court (regulator) — Approves capital reduction under Irish law
• NYSE (regulator) — Determines routine vs. non-routine matters

FAQ

Industry Context

Prothena operates in the biotechnology sector, focusing on developing therapies for rare diseases. This industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies often rely on strategic financial maneuvers, such as capital adjustments, to fund ongoing research and development or to return value to shareholders.

Regulatory Implications

The proposed capital reduction is subject to Irish company law, which requires specific procedures and shareholder approval to create distributable reserves. Compliance with these regulations is crucial for Prothena to legally execute future distributions like share redemptions or dividends.

What Investors Should Do

1. Review the Proxy Statement thoroughly before the November 18, 2025 deadline.
2. Vote 'FOR' Proposal No. 1 at the Extraordinary General Meeting on November 19, 2025.
3. Ensure your proxy is submitted by the November 18, 2025 deadline.

Key Dates

• 2025-11-19: Extraordinary General Meeting (EGM) — Shareholders will vote on a capital reduction proposal to create distributable reserves for potential share repurchases, dividends, or other distributions.
• 2025-09-24: Record Date for EGM — Establishes the list of shareholders eligible to vote at the EGM.
• 2025-10-07: Proxy Materials Availability — Proxy statement and related materials made available to shareholders, initiating the proxy voting period.
• 2025-11-18: Proxy Voting Deadline — Final deadline for shareholders to submit their votes via internet, telephone, or written proxy.
• 2025-08-04: Press Release on Share Redemption Program — Previously referenced a potential share redemption program, which the current capital reduction aims to facilitate.

Glossary

Distributable Reserves

Profits that a company is legally allowed to distribute to shareholders as dividends or through share buybacks. (The capital reduction is specifically designed to create these reserves, enabling Prothena to return capital to shareholders.)

Ordinary Shares

The basic form of stock that represents ownership in a company, typically carrying voting rights. (These are the voting securities of Prothena, with 53,829,928 issued and outstanding as of the record date.)

Par Value

A nominal face value assigned to a security by the issuer, often a very small amount. (Prothena's ordinary shares have a par value of $0.01, indicating a low nominal value per share.)

Quorum

The minimum number of shareholders required to be present at a meeting for it to be validly held. (A quorum for Prothena's EGM requires shareholders holding a majority of the issued and outstanding ordinary shares (26,914,965 shares) to be represented.)

Special Resolution

A resolution that requires a higher majority vote than a simple majority, typically 75% or more, to pass. (The capital reduction proposal requires a 75% approval threshold of votes cast, classifying it as a special resolution.)

DEF 14A

A proxy statement filed with the SEC by publicly traded companies, providing information about matters to be voted on at shareholder meetings. (This document outlines the details of the EGM, including the capital reduction proposal and management's recommendations.)

Year-Over-Year Comparison

This filing is a proxy statement for an Extraordinary General Meeting, focused on a specific corporate action (capital reduction) rather than a comprehensive annual review. Therefore, direct year-over-year comparisons of financial metrics like revenue growth or margins are not applicable to this document. The key information relates to the upcoming EGM's date, voting requirements, and the strategic rationale behind the proposed capital restructuring.

Key Financial Figures

• $0.01 — es of Prothena are our ordinary shares, $0.01 par value per share ("ordinary shares")
• $49.3 million — December 31, 2024, we had approximately $49.3 million in distributable reserves. The amount
• $479.7 million — of December 31, 2024, was approximately $479.7 million. In order to facilitate the creation o

Filing Documents

• ny20053507x2_def14a.htm (DEF 14A) — 276KB
• logo_footerprothena.jpg (GRAPHIC) — 9KB
• logo_prothena.jpg (GRAPHIC) — 23KB
• logo_prothenax1.jpg (GRAPHIC) — 22KB
• ny20053507x1_pc01.jpg (GRAPHIC) — 519KB
• ny20053507x1_pc02.jpg (GRAPHIC) — 773KB
• sig_danielgwelch.jpg (GRAPHIC) — 18KB
• sig_genegkinney.jpg (GRAPHIC) — 12KB
• sig_michaeljmalecek.jpg (GRAPHIC) — 23KB
• sig_michaeljmalecekx1.jpg (GRAPHIC) — 18KB
• 0001140361-25-037500.txt ( ) — 2228KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 8 HOUSEHOLDING OF PROXY MATERIALS 10 TABLE OF CONTENTS PROTHENA CORPORATION PLC Registered in Ireland - No. 518146 77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland PROXY STATEMENT FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 19, 2025 GENERAL INFORMATION The Board of Directors of Prothena Corporation plc is soliciting your proxy to vote at the Extraordinary General Meeting of Shareholders to be held on Wednesday, November 19, 2025, at 4:00 p.m. local time, and any adjournment or postponement of that meeting (the "EGM"). The EGM will be held at the offices of the Company's legal counsel, A&L Goodbody LLP, 25 North Wall Quay, Dublin 1, D01 H104, Ireland. We have elected to use the internet as our primary means of providing our proxy materials to shareholders. Accordingly, on or about October 7, 2025, we are making this Proxy Statement, the accompanying form of proxy card, and the accompanying Notice of Extraordinary General Meeting of Shareholders available on the internet and mailing a Notice of Internet Availability of Proxy Materials to shareholders of record as of close of business on September 24, 2025 (the "Record Date"). Brokers and other nominees who hold shares on behalf of beneficial owners will be sending their own similar notice. All shareholders as of the Record Date will have the ability to access our proxy materials on the website referred to in the Notice of Internet Availability of Proxy Materials or request to receive a printed set of the proxy materials. Instructions on how to request a printed copy by mail or electronically may be found in the Notice of Internet Availability of Proxy Materials and on the website referred to in the notice, including an option to request paper copies on an ongoing basis. We intend to mail this Proxy Statement, together with the accompanying form of proxy card and

View Full Filing

View this DEF 14A filing on SEC EDGAR